Overview

Peptide Therapeutics Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Peptides are one of the crucial therapeutic molecule classes developed by multiple biotech and pharma companies for attaining the discovery of targeted drugs for many ailments. As of now, there are over 790 peptide drugs under clinical tests and over 190 commercial peptide-based drugs are available in the market. Proteins and therapeutic peptides have proven to be primary drug candidates for over several decades. Many key players have specialised in manufacturing and developing products based on peptides from newer drug candidates to medical diagnostic devices. The soaring rise in the time span and cost of developing a traditional drug leading to the pharmaceutical companies and researchers in developing novel products that are cost-effective that are based on the strategy of synthetic peptides.
Peptides have low toxicity levels due to their lower instance interaction with other molecules and due to the easy metabolism into their amino acid component residues. Pharma companies are more inclined towards peptides as they are easy to manufacture. The rising needs of peptides owing to innovative development of drugs with the bioactive properties of peptides is one of the primary interests of pharma companies. Such factors are responsible for the proliferation of the market.

Peptide Therapeutics Market

Market Segmentation:

By Drug Type
•   Generic Drugs
•   Innovative Drugs
By Manufacturer
•   In-House
•   Outsourced
By Application
•   Cancer
•   Cardiovascular Disorder
•   Metabolic Disorder
•   Pain
•   Respiratory Disorder
•   Dermatology
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is classified into drug type, manufacturer, application and region. The type segment is fragmented into generic and innovative drugs. The innovative peptides held the largest peptide therapeutics market share, and this can be attributed to the high rate of prescription and a rise in the number of investments by major pharma companies in developing advanced drugs. However, it is the generic segment that is predicted to experience substantial growth during the forecast period. Furthermore, patent losses to multiple branded drugs is predicted to boost the segment growth as generic players can offer low-cost options to mainstream drugs. The manufacturer segment is categorised into in-house and outsourced. The in-house segment is predicted to lead the market as most of the players are developing in-house peptide therapeutics due to strict regulations and high outsourcing cost. The application segment is bifurcated into cancer, cardiovascular disorder, metabolic disorder, pain, respiratory disorder and dermatology. The cancer segment led the market in 2018 in terms of revenue generation and this is primarily credited to a rising incidence of cancer across the world and increased peptide therapeutic prescription for treating cancer.

Regional Analysis:

The North America region is anticipated to dominate the market, and this is primarily due to a rise in the levels of awareness related to peptide therapeutics, rising insistence for cancer diagnostics along with rising biotech industry. Furthermore, rising expenditure on research and development activities shall flourish the growth of the market.

Competitive Landscape:

Some of the prominent market players are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., Lonza Inc., Sanofi, Bristol-Myers Squibb (BMS), AstraZeneca PLC, GlaxoSmithKline plc (GSK), Novartis AG, Novo Nordisk A/S.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global peptide therapeutics market by drug type, by manufacturer, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com